abstract |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17.beta.-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17.beta.hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17.beta.-hydroxysteroid dehydrogenase. |